The Malignant Pleural Effusion drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Pleural Effusion. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Malignant Pleural Effusion by 11 companies/universities/institutes. The top development phase for Malignant Pleural Effusion is preclinical with four drugs in that stage. The Malignant Pleural Effusion pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Malignant Pleural Effusion pipeline products market are: Genelux, Simcere Pharmaceutical Group and Wuhan YZY Biopharma.
The key targets in the Malignant Pleural Effusion pipeline products market include CD3, Epithelial Cell Adhesion Molecule, and Tubulin.
The key mechanisms of action in the Malignant Pleural Effusion pipeline product include Tubulin Inhibitor with one drug in Preclinical. The Malignant Pleural Effusion pipeline products include nine routes of administration with the top ROA being Intrapleural and seven key molecule types in the Malignant Pleural Effusion pipeline products market including Small Molecule, and Oncolytic Virus.
Malignant Pleural Effusion overview
Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.
For a complete picture of Malignant Pleural Effusion’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
